Human medicines European public assessment report (EPAR): Tafinlar, dabrafenib, Date of authorisation: 26/08/2013, Revision: 40, Status: Authorised

Agenda of the CVMP meeting 19-21 May 2026

Presentation - CTIS Bitesize Talk: End of transition period and notifications including serious breaches

Human medicines European public assessment report (EPAR): Spexotras, trametinib, Date of authorisation: 05/01/2024, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Procysbi, mercaptamine, Date of authorisation: 05/09/2013, Revision: 18, Status: Authorised

Human medicines European public assessment report (EPAR): Arexvy, Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Date of authorisation: 06/06/2023, Revision: 11, Status: Authorised

Human medicines European public assessment report (EPAR): Zoledronic acid medac, zoledronic acid, Date of authorisation: 03/08/2012, Revision: 15, Status: Withdrawn

Application form for the involvement of healthcare professionals’ organisations in the activities of the European Medicines Agency

Human medicines European public assessment report (EPAR): Ibrance, palbociclib, Date of authorisation: 09/11/2016, Revision: 25, Status: Authorised

Executive Steering Group on Shortages of Medical Devices